BB 1101

Drug Profile

BB 1101

Latest Information Update: 08 Nov 1996

Price : $50

At a glance

  • Originator British Biotech
  • Class Antirheumatics; Peptides
  • Mechanism of Action Metalloprotease inhibitors; Peptide hydrolase inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Encephalomyelitis; Rheumatic disorders

Most Recent Events

  • 08 Nov 1996 Discontinued-Preclinical for Encephalomyelitis in United Kingdom (Unknown route)
  • 08 Nov 1996 Discontinued-Preclinical for Rheumatic disorders in United Kingdom (Unknown route)
  • 16 Feb 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top